Search Results - "Marais, A.David"

Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease by Marais, A.David

“…Apolipoprotein E (apoE), a 34 kDa circulating glycoprotein of 299 amino acids, predominantly synthesised in the liver, associates with triglyceride-rich…”
Get full text

Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia by Raal, Frederick J., Pappu, Anuradha S., Illingworth, D.Roger, Pilcher, Gillian J., Marais, A.David, Firth, Jean C., Kotze, Maritha J., Heinonen, Therese M., Black, Donald M.

“…Patients with homozygous familial hypercholesterolaemia (HoFH) have markedly elevated low density lipoprotein (LDL) cholesterol levels that are refractory to…”
Get full text

Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia by Blom, Dirk J, Byrnes, Pamela, Jones, Sheena, Marais, A David

“…Dysbetalipoproteinemia, an uncommon but highly atherogenic mixed hyperlipidemia due to the accumulation of remnants of triglyceride-rich lipoproteins, is…”
Get full text

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab by Villard, Elise F, Thedrez, Aurélie, Blankenstein, Jorg, Croyal, Mikaël, Tran, Thi-Thu-Trang, Poirier, Bruno, Le Bail, Jean-Christophe, Illiano, Stéphane, Nobécourt, Estelle, Krempf, Michel, Blom, Dirk J, Marais, A David, Janiak, Philip, Muslin, Anthony J, Guillot, Etienne, Lambert, Gilles

“…To elucidate how the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor alirocumab modulates lipoprotein(a) [Lp(a)] plasma levels, the authors…”
Get full text

Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial by McCrindle, Brian W, Ose, Leiv, Marais, A.David

“…Objective To determine the safety and efficacy of atorvastatin (10 to 20 mg) in children and adolescents with familial hypercholesterolemia or severe…”
Get full text

Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia by Raal, Frederick J., Marais, A.David, Klepack, Ellen, Lovalvo, Jennifer, McLain, Richard, Heinonen, Therese

“…This study assessed the efficacy and safety of avasimibe (CI-1011), an inhibitor of acyl coenzyme A-cholesterol acyltransferase (ACAT) in subjects with…”
Get full text

A brief review paper of the efficacy and safety of atorvastatin in early clinical trials by Bakker-Arkema, Rebecca G, Best, James, Fayyad, Rana, Heinonen, Therese M, Marais, A.David, Nawrocki, James W, Black, Donald M

“…Preclinical and clinical data on atorvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, indicate that it has superior…”
Get full text

Two novel point mutations causing receptor-negative familial hypercholesterolemia in a South African Indian homozygote by Langenhoven, Elzet, Warnich, Louise, Thiart, Rochelle, Rubinsztein, David C., van der Westhuyzen, Deneys R., Marais, A.David, Kotze, Maritha J.

“…Two novel point mutations have been identified in the low density lipoprotein receptor (LDLR) gene of a South African Indian patient with a clinical diagnosis…”
Get full text

Plasma exchange for homozygous familial hypercholesterolaemia: the Cape Town experience by Marais, A D, Wood, L, Firth, J C, Hall, J M, Jacobs, P

“…Homozygous familial hypercholesterolaemia (FH) is a rare disorder having a greater frequency in populations with founder effects for the mutations in low…”
Get more information